Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Merck & Co., Inc.
Merck & Co., Inc. News
Feb 21, 2025 - accessnewswire.com
Merck & Co., Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - MRK
Feb 21, 2025 - zacks.com
Why Merck (MRK) is a Great Dividend Stock Right Now
Feb 21, 2025 - accessnewswire.com
Levi & Korsinsky Reminds Merck Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - MRK
Feb 21, 2025 - businesswire.com
Law Offices of Howard G. Smith Encourages Merck & Co (MRK) Investors To Inquire About Securities Fraud Class Action
Merck & Co., Inc. Quantitative Score
About Merck & Co., Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Merck & Co., Inc. Earnings & Revenue
Merck & Co., Inc. Financials
Table Compare
Compare MRK metrics with: | |||
|---|---|---|---|
Earnings & Growth | MRK | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | MRK | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | MRK | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | MRK | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Merck & Co., Inc. Income
Merck & Co., Inc. Balance Sheet
Merck & Co., Inc. Cash Flow
Merck & Co., Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Buy |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Merck & Co., Inc. Dividends
| Yield (TTM) | Dividend (TTM) | |
|---|---|---|
Infinity% | 3.1600 |
| Payment Date | Dividend | Frequency |
|---|---|---|
| 2025-04-07 | 0.81 | Quarterly |
| 2025-01-08 | 0.81 | Quarterly |
| 2024-10-07 | 0.77 | Quarterly |
| 2024-07-08 | 0.77 | Quarterly |
| 2024-04-05 | 0.77 | Quarterly |
Merck & Co., Inc. Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Merck & Co., Inc. Executives
| Name | Role |
|---|---|
| Mr. Robert M. Davis J.D. | Chairman, President & Chief Executive Officer |
| Dr. Dean Y. Li M.D., Ph.D. | Executive Vice President & President of Merck Research Laboratories |
| Ms. Caroline Litchfield | Executive Vice President & Chief Financial Officer |
| Ms. Jennifer L. Zachary J.D. | Executive Vice President & General Counsel |
| Mr. Sanat Chattopadhyay | Executive Vice President & President of Merck Manufacturing Division |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Robert M. Davis J.D. | Chairman, President & Chief Executive Officer | Male | 1967 | 5.57M |
| Dr. Dean Y. Li M.D., Ph.D. | Executive Vice President & President of Merck Research Laboratories | 1964 | 3.61M | |
| Ms. Caroline Litchfield | Executive Vice President & Chief Financial Officer | Female | 1969 | 3.09M |
| Ms. Jennifer L. Zachary J.D. | Executive Vice President & General Counsel | Female | 1978 | 2.73M |
| Mr. Sanat Chattopadhyay | Executive Vice President & President of Merck Manufacturing Division | Male | 1960 | 2.49M |
Merck & Co., Inc. Insider Trades
| Date | 19 Feb |
| Name | Oosthuizen Johannes Jacobus |
| Role | President, U.S. Market |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 8500 |
| Date | 13 Feb |
| Name | Williams David Michael |
| Role | EVP,Chief Info&Digital Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 6000 |
| Date | 8 Feb |
| Name | Oosthuizen Johannes Jacobus |
| Role | President, U.S. Market |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 13002 |
| Date | 8 Feb |
| Name | Oosthuizen Johannes Jacobus |
| Role | President, U.S. Market |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 6404 |
| Date | 8 Feb |
| Name | Oosthuizen Johannes Jacobus |
| Role | President, U.S. Market |
| Transaction | Disposed |
| Type | M-Exempt |
| Shares | 13002 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 19 Feb | Oosthuizen Johannes Jacobus | President, U.S. Market | Disposed | S-Sale | 8500 |
| 13 Feb | Williams David Michael | EVP,Chief Info&Digital Officer | Disposed | S-Sale | 6000 |
| 8 Feb | Oosthuizen Johannes Jacobus | President, U.S. Market | Acquired | M-Exempt | 13002 |
| 8 Feb | Oosthuizen Johannes Jacobus | President, U.S. Market | Disposed | F-InKind | 6404 |
| 8 Feb | Oosthuizen Johannes Jacobus | President, U.S. Market | Disposed | M-Exempt | 13002 |